{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kim Y"],"funding":["Ministry of Food and Drug Safety","GC BioPharma corporate"],"pagination":["2428516"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11610554"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["The COVID-19 pandemic forced the rapid development of methods to measure humoral and cellular immunity against SARS-CoV-2. The lack of a global standardized protocol and the high variability of intra- and inter-assay precision of the T-cell response made it difficult to compare T-cell assay results with those of other laboratories. The interferon-gamma enzyme-linked immunosorbent spot (IFN-γ ELISpot) assay for immunogenicity evaluation was validated using naturally infected donor peripheral blood mononuclear cells, a commercially available IFN-γ ELISpot kit, and a SARS-CoV-2 specific peptide pool. Depending on anti-CD3 and peptide pool stimulation, the mean coefficients of variation (CVs) of the intra-assay precision were 19.0% and 13.4%, respectively. The mean CVs of the inter-assay preci"],"journal":["Human vaccines & immunotherapeutics"],"pubmed_title":["Validation of an interferon-gamma enzyme-linked immunosorbent spot assay to evaluate cell-mediated immunity against severe acute respiratory syndrome coronavirus 2."],"pmcid":["PMC11610554"],"funding_grant_id":["21172MFDS181"],"pubmed_authors":["Park H","Jang EJ","Choi ST","Lee KM","Xayaheuang S","Hwang JY","Kim Y"],"additional_accession":[]},"is_claimable":false,"name":"Validation of an interferon-gamma enzyme-linked immunosorbent spot assay to evaluate cell-mediated immunity against severe acute respiratory syndrome coronavirus 2.","description":"The COVID-19 pandemic forced the rapid development of methods to measure humoral and cellular immunity against SARS-CoV-2. The lack of a global standardized protocol and the high variability of intra- and inter-assay precision of the T-cell response made it difficult to compare T-cell assay results with those of other laboratories. The interferon-gamma enzyme-linked immunosorbent spot (IFN-γ ELISpot) assay for immunogenicity evaluation was validated using naturally infected donor peripheral blood mononuclear cells, a commercially available IFN-γ ELISpot kit, and a SARS-CoV-2 specific peptide pool. Depending on anti-CD3 and peptide pool stimulation, the mean coefficients of variation (CVs) of the intra-assay precision were 19.0% and 13.4%, respectively. The mean CVs of the inter-assay preci","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-04T00:21:31.038Z","creation":"2025-04-04T00:21:31.038Z"},"accession":"S-EPMC11610554","cross_references":{"pubmed":["39610025"],"doi":["10.1080/21645515.2024.2428516"]}}